plus_logo.png
Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement
March 10, 2025 07:30 ET | Plus Therapeutics Inc.
Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement
plus_logo.png
Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma
March 07, 2025 07:30 ET | Plus Therapeutics Inc.
Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda
plus_logo.png
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer
March 06, 2025 07:30 ET | Plus Therapeutics Inc.
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with L
plus_logo.png
Plus Therapeutics Announces New Employment Inducement Grants
March 05, 2025 16:01 ET | Plus Therapeutics Inc.
Plus Therapeutics Announces New Employment Inducement Grants
plus_logo.png
Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds
March 04, 2025 14:06 ET | Plus Therapeutics Inc.
Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds
ymabslogo.png
Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments
March 04, 2025 06:35 ET | Y-mAbs Therapeutics, Inc.
Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments
plus_logo.png
Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary
February 24, 2025 07:30 ET | Plus Therapeutics Inc.
Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary
plus_logo.png
Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer
February 20, 2025 07:30 ET | Plus Therapeutics Inc.
Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer
plus_logo.png
Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program
February 18, 2025 07:30 ET | Plus Therapeutics Inc.
Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program
MonoparTherapeuticsInc..png
Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu
December 05, 2024 16:21 ET | Monopar Therapeutics Inc.
WILMETTE, Ill., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet...